lundi 17 juin 2019

Onco Actu du 17 juin 2019


1.1 BIOLOGIE - GÉNOME



Small, furry and powerful: are mouse lemurs the next big thing in genetics? [Nature]










3.1 PRÉVENTION - TABAC



Quitting smoking is hard. Mindfulness hacks the habit loop, offering a new approach [STAT]











5. TRAITEMENTS



For stomach cancer, aerosol chemotherapy offers breath of hope [France 24]











Reports of the Demise of Chemotherapy Have Been Greatly Exaggerated [AJMC]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells [NCI]










5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Cancer-killing virus boosts immunotherapy in hard-to-treat cancer [Institute of Cancer Research]











5.16 TRAITEMENTS - CHIRURGIE



Artificial nose identifies malignant tissue in brain tumours during surgery [Tempere University]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019 [EMA]










5.4 TRAITEMENTS - ECONOMIE



Understanding Price Growth in the Market for Targeted Oncology Therapies [Healthcare Economist]










5.9.3 EHA



Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures [Regeneron]











ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting [ArQule]











BerGenBio posts updated data on trial of elderly AML patients [Fierce Biotech]











Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 [Amgen]











Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) [BMS]











BeiGene touts 'encouraging' response rates as the Chinese biotech mounts challenge to BTK, PD-1 leaders [EndPoints]











Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) [Novartis]











Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates [EndPoints]











6. LUTTE CONTRE LES CANCERS



The scientists on a mission to revolutionise brain tumour research [Cancer Research UK]










NCAB asks for help from administration as NCI deals with deluge of grant applications [The Cancer Letter]










6.10.1 POLITIQUES (USA)



Amgen, Merck, and Eli Lilly sue over Trump administration policy to require drug prices in TV ads [STAT]











Inhumane or unavoidable? As Congress scrutinizes an increase in monkey research, scientists defend its necessity [STAT]











Drug Makers Sue to Block Requirement for Listing Prices in TV Ads [NY Times]











Drug Prices Are a Populist Campaign Issue. Here Are the Latest Proposals to Lower Costs. [NY Times]











6.7 DMP, BIG DATA & APPLIS



After losing its CMO to the FDA, Roche's Flatiron Health nabs biopharma veteran [Fierce Biotech]